Adding Tucatinib Improved PFS, OS in Metastatic HER2+ Breast Cancer
Survival benefits were maintained among those with brain metastases.
Breast Cancer News
BREAST CANCER ADVISOR
Breast Cancer News
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
High BMI May Cut Overall Survival in HER2+ Metastatic Breast Cancer
BMI had no impact on progression-free survival to first-line chemotherapy.
CMS Covers Next-Generation Sequencing for Breast and Ovarian Cancer
CMS recently announced that patients with germline ovarian or breast cancer would be covered for diagnostic testing that uses next-generation sequencing.
Conference Organizers Can Help Oncologists Distill Practice-Changing Data
A SABCS 2019 session encouraged oncologists to scrutinize whether presentations are practice changing, and included a look at controversial data from KEYNOTE-522.
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Emerging Therapeutic Approaches for Metastatic HER2-Positive Breast Cancer
Content was developed by PRI Healthcare Solutions, a division of Haymarket Media, Inc. Advertising support received from Seattle Genetics, Inc. Seattle Genetics, Inc. did not influence or provide oversight over content. In this video, breast medical oncologist, Carey Anders, MD, medical director of the Duke Center for Brain and Spine Metastasis at the Duke…
Oncotype DX Shown to Work Differently in Men and Women With Breast Cancer
The tool is still diagnostically useful in both cases, it just may require sex-specific guidelines for use.
Updated Guidelines Issued for ER, PgR Testing in Breast Cancer
Clinicians should be prepared to discuss limited data for benefit of endocrine tx in ER-low positive cases.
Update to ASCO/CAP Guideline in Breast Cancer: No Sweeping Changes, but Many Refinements
The ASCO/CAP Expert Panel continues to recommend IHC as the only primary screening test for predicting benefit of endocrine therapy in breast cancer.
Bevacizumab Adoption Tied to Use by Peers
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Lack of Insurance Tied to Later Stage of Breast Cancer at Diagnosis
Almost half of higher stage of disease at diagnosis in racial/ethnic minorities explained by insurance status.
Notification Laws May Not Increase Knowledge of Dense Breast Risks
Women with lower education may be less likely to gain awareness of breast density due to the laws.
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Cardiac Resynchronization Therapy Associated With Substantial Increase in LVEF in Patients With Chemotherapy-Induced Cardiomyopathy
Cardio-oncology is an emerging field focusing on the detection, monitoring, and treatment of cardiac dysfunction related to systemic or radiation therapy.
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer News
